Stockreport

Capricor signals pivotal HOPE-3 data imminent as FDA review process advances for deramiocel [Seeking Alpha]

Capricor Therapeutics, Inc.  (CAPR) 
Last capricor therapeutics, inc. earnings: 3/18 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: capricor.com/investors
PDF CEO Linda Marbán highlighted the imminent top line readout from the HOPE-3 Phase III clinical study of deramiocel for Duchenne muscular dystrophy, stating this is "just [Read more]